Literature DB >> 16711013

FasL expression in colorectal carcinoma and its significance in immune escape of cancer.

Qiang Tong1, Ke Liu, Guobin Wang.   

Abstract

To study the significance of FasL expression in immune escape of colorectal carcinoma, FasL protein expression and the number of tumor infiltrating lymphocytes (TILs) in 80 specimens of colorectal carcinoma were detected by immunohistochemitry. The mRNA of FasL was measured by in situ hybridization in the consecutive tissue slices of 80 colorectal carcinomas respectively. Using terminal deoxynucleotidyl transferase-mediaed dUTP nick end labeling (TUNEL), apoptotic cells were detected in 80 specimens of colorectal carcinoma. The expression of FasL was detected in all 80 specimens, but it was not even in the same or among different tissues. In the consecutive tissue slices, the location of expression of FasL protein corresponded with that of FasL mRNA. In those with FasL extensive expression, the number of TILs was less than that of FasL weak expression (P < 0.05), and the apoptotic index (AI) of TILs was higher and that of tumor cells was lower than that of FasL with weak expression respectively (P < 0.01). The Al of TILs was correlated with that of tumor cells (r = -0.631, P < 0.01). It was suggested that colorectal carcinoma cells can induce the apoptosis of TILs through the expression of FasL, which can counterattack the immune system. This may be one of the mechanisms of immune evasion in colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711013     DOI: 10.1007/bf02828044

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

1.  Fas-related apoptosis in gastric adenocarcinoma.

Authors:  Sung-Chul Lim
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

2.  Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.

Authors:  K M Ropponen; M J Eskelinen; P K Lipponen; E Alhava; V M Kosma
Journal:  J Pathol       Date:  1997-07       Impact factor: 7.996

3.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

Authors:  K Okada; K Komuta; S Hashimoto; S Matsuzaki; T Kanematsu; T Koji
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

5.  Expression of Fas ligand is an early event in colorectal carcinogenesis.

Authors:  M Shimoyama; T Kanda; L Liu; Y Koyama; T Suda; Y Sakai; K Hatakeyama
Journal:  J Surg Oncol       Date:  2001-01       Impact factor: 3.454

6.  Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.

Authors:  Tetsuo Shukuwa; Ichiro Katayama; Takehiko Koji
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

7.  Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.

Authors:  Tae-Bum Lee; Young-Don Min; Sung-Chul Lim; Kyung-Jong Kim; Ho-Jong Jeon; Seok-Min Choi; Cheol-Hee Choi
Journal:  J Gastroenterol Hepatol       Date:  2002-01       Impact factor: 4.029

8.  Fas ligand expression is correlated with metastasis in colorectal carcinoma.

Authors:  Tadahiro Nozoe; Mitsuhiro Yasuda; Masayuki Honda; Sadaaki Inutsuka; Daisuke Korenaga
Journal:  Oncology       Date:  2003       Impact factor: 2.935

9.  Fas ligand expression in human pancreatic cancer.

Authors:  Tetsuo Ohta; Ayman Elnemr; Hirohisa Kitagawa; Masato Kayahara; Hiroyuki Takamura; Takashi Fujimura; Gen-Ichi Nishimura; Koichi Shimizu; Shuang-Qin Yi; Koichi Miwa
Journal:  Oncol Rep       Date:  2004-10       Impact factor: 3.906

  9 in total
  1 in total

1.  In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.

Authors:  Iotefa Teiti; Bertrand Florie; Christine Pich; Rémi Gence; Isabelle Lajoie-Mazenc; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  Front Oncol       Date:  2015-07-14       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.